Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 362-366

  Wang, Yong ^a   Wang, He ^a   Li, Chuan Yuan ^a   Yuan, Fan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVANS BLUE; LUCIFERASE;

ADENOVIRUS VECTOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CODE; IMAGING SYSTEM; INFUSION RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; LIVER; LUCIFERASES; MICE; MICE, INBRED BALB C;

EID: 33644974100     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0266     Document Type: Article

References (28)

1. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 1997;26:71-90.
2. McGuire S, Yuan F. Quantitative analysis of intratumoral infusion of color molecules. Am J Physiol Heart Circ Physiol 2001;281:H715-21.
3. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-80.
4. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng 2001;29:1150-8.
5. Zhang XY, Luck J, Dewhirst MW, Yuan F. Interstitial hydraulic conductivity in a fibrosarcoma. Am J Physiol Heart Circ Physiol 2000; 279:H2726-34.
6. Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000;1:263-74.
7. Lu Y, Carraher J, Zhang Y, et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999;6:64-72.
8. Steiner MS, Zhang Y, Carraher J, Lu Y. In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther 1999;6: 456-64.
9. Tang DC, Johnston SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther 1994;1:15-20.
10. Zhang R, Straus FH, DeGroot LJ. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology 1999;140:2152-8.
11. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997;4:1069-76.
12. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996;3: 11-7.
13. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003;2: 1233-42.
14. Wang Y, Liu S, Li CY, Yuan F. A novel method for viral gene delivery in solid tumors. Cancer Res 2005;65:7541-5.
15. Wang Y, Yang Z, Liu S, et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005;92:1414-20.
16. Wang Y, Yuan F. Delivery of viral vectors to tumor cells: Extracellular transport, systemic distribution, and strategies for improvement. Ann Biomed Eng. In press 2006.
17. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19:838-42.
18. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001;38:177-92.
19. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, editor. Gene transfer and expression protocols. Clifton: Humana Press; 1991. p. 109-28.
20. Dillehay LE. Decreasing resistance during fast infusion of a subcutaneous tumor. Anticancer Res 1997;17:461-6.
21. Boucher Y, Brekken C, Netti PA, Baxter LT, Jain RK. Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. Br J Cancer 1998;78:1442-8.
22. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
23. Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2000;2:223-32.
24. Tjuvajev JG, Chen SH, Joshi A, et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 1999;59:5186-93.
25. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther 2005;12: 427-36.
26. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157-66.
27. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health, Recombinant DNA Advisory Committee. Hum Gene Ther 2002;13:3-13.
28. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002;13:163-75.